Long-term clinical observation of patients with heterozygous KIF1A variants.

KIF1A cerebellar atrophy optic radiation peripheral neuropathy spastic paraplegia

Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
17 May 2024
Historique:
received: 10 03 2024
accepted: 27 04 2024
medline: 18 5 2024
pubmed: 18 5 2024
entrez: 17 5 2024
Statut: aheadofprint

Résumé

KIF1A-related disorders (KRDs) encompass recessive and dominant variants with wide clinical variability. Recent genetic investigations have expanded the clinical phenotypes of heterozygous KIF1A variants. However, there have been a few long-term observational studies of patients with heterozygous KIF1A variants. A retrospective chart review of consecutive patients diagnosed with spastic paraplegia at Miyagi Children's Hospital from 2016 to 2020 identified six patients with heterozygous KIF1A variants. To understand the long-term changes in clinical symptoms, we examined these patients in terms of their characteristics, clinical symptoms, results of electrophysiological and neuroimaging studies, and genetic testing. The median follow-up period was 30 years (4-44 years). This long-term observational study showed that early developmental delay and equinus gait, or unsteady gait, are the first signs of disease onset, appearing with the commencement of independent walking. In addition, later age-related progression was observed in spastic paraplegia, and the appearance of axonal neuropathy and reduced visual acuity were characteristic features of the late disease phenotype. Brain imaging showed age-related progression of cerebellar atrophy and the appearance of hyperintensity of optic radiation on T2WI and FLAIR imaging. Long-term follow-up revealed a pattern of steady progression and a variety of clinical symptoms, including spastic paraplegia, peripheral neuropathy, reduced visual acuity, and some degree of cerebellar ataxia. Clinical variability between patients was observed to some extent, and therefore, further studies are required to determine the phenotype-genotype correlation.

Identifiants

pubmed: 38760879
doi: 10.1002/ajmg.a.63656
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e63656

Subventions

Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP23ek0109674
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP23ek0109549
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP23ek0109617
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : JP23ek0109648
Organisme : Japanese Society for the Promotion of Science KAKENHI
ID : JP23H02877
Organisme : Takeda Science Foundation
Organisme : Astellas Pharma

Informations de copyright

© 2024 Wiley Periodicals LLC.

Références

Anazawa, Y., Kita, T., Iguchi, R., Hayashi, K., & Niwa, S. (2022). De novo mutations in KIF1A‐associated neuronal disorder (KAND) dominant‐negatively inhibit motor activity and axonal transport of synaptic vesicle precursors. Proceedings of the National Academy of Sciences of the United States of America, 119, e2113795119.
Boyle, L., Rao, L., Kaur, S., Fan, X., Mebane, C., Hamm, L., Thornton, A., Ahrendsen, J. T., Anderson, M. P., Christodoulou, J., Gennerich, A., Shen, Y., & Chung, W. K. (2021). Genotype and defects in microtubule‐based motility correlate with clinical severity in KIF1A‐associated neurological disorder. Human Genetics and Genomics Advances, 2(2), 100026.
Cai, F., & Zhang, J. (1997). Study of nerve conduction and late responses in normal Chinese infants, children, and adults. Journal of Child Neurology, 12, 13–18.
Cheon, C. K., Lim, S. H., Kim, Y. M., Kim, D., Lee, N. Y., Yoon, T. S., Kim, N. S., Kim, E., & Lee, J. R. (2017). Autosomal dominant transmission of complicated hereditary spastic paraplegia due to a dominant negative mutation of KIF1A, SPG30 gene. Scientific Reports, 7, 12527.
Erlich, Y., Edvardson, S., Hodges, E., Zenvirt, S., Thekkat, P., Shaag, A., Dor, T., Hannon, G. J., & Elpeleg, O. (2011). Exome sequencing and disease‐network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis. Genome Research, 21, 658–664.
Esmaeeli Nieh, S., Madou, M. R., Sirajuddin, M., Fregeau, B., McKnight, D., Lexa, K., Strober, J., Spaeth, C., Hallinan, B. E., Smaoui, N., Pappas, J. G., Burrow, T. A., McDonald, M. T., Latibashvili, M., Leshinsky‐Silver, E., Lev, D., Blumkin, L., Vale, R. D., Barkovich, A. J., & Sherr, E. H. (2015). De novo mutations in KIF1A cause progressive encephalopathy and brain atrophy. Annals of Clinical Translational Neurology, 2, 623–635.
Hamdan, F. F., Gauthier, J., Araki, Y., Lin, D. T., Yoshizawa, Y., Higashi, K., Park, A. R., Spiegelman, D., Dobrzeniecka, S., Piton, A., Tomitori, H., Daoud, H., Massicotte, C., Henrion, E., Diallo, O., S2D Group, Shekarabi, M., Marineau, C., Shevell, M., … Michaud, J. L. (2011). Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. American Journal of Human Genetics, 88, 306–316.
Helsmoortel, C., Vulto‐van Silfhout, A. T., Coe, B. P., Vandeweyer, G., Rooms, L., van den Ende, J., Schuurs‐Hoeijmakers, J. H., Marcelis, C. L., Willemsen, M. H., Vissers, L. E., Yntema, H. G., Bakshi, M., Wilson, M., Witherspoon, K. T., Malmgren, H., Nordgren, A., Annerén, G., Fichera, M., Bosco, P., … Van der Aa, N. (2014). A SWI/SNF‐related autism syndrome caused by de novo mutations in ADNP. Nature Genetics, 46, 380–384.
Klebe, S., Lossos, A., Azzedine, H., Mundwiller, E., Sheffer, R., Gaussen, M., Marelli, C., Nawara, M., Carpentier, W., Meyer, V., Rastetter, A., Martin, E., Bouteiller, D., Orlando, L., Gyapay, G., el‐Hachimi, K. H., Zimmerman, B., Gamliel, M., Misk, A., … Stevanin, G. (2012). KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: Distinct phenotypes according to the nature of the mutations. European Journal of Human Genetics, 20, 645–649.
Lee, J. R., Srour, M., Kim, D., Hamdan, F. F., Lim, S. H., Brunel‐Guitton, C., Décarie, J. C., Rossignol, E., Mitchell, G. A., Schreiber, A., Moran, R., van Haren, K., Richardson, R., Nicolai, J., Oberndorff, K. M. E. J., Wagner, J. D., Boycott, K. M., Rahikkala, E., Junna, N., … Michaud, J. L. (2014). De novo mutations in the motor domain of KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy. Human Mutation, 36, 69–78.
Nair, A., Greeny, A., Rajendran, R., Abdelgawad, M. A., Ghoneim, M. M., Raghavan, R. P., Sudevan, S. T., Mathew, B., & Kim, H. (2023). KIF1A‐associated neurological disorder: An overview of a rare mutational disease. Pharmaceuticals (Basel), 16, 147.
Nemani, T., Steel, D., Kaliakatsos, M., DeVile, C., Ververi, A., Scott, R., Getov, S., Sudhakar, S., Male, A., Mankad, K., Genomics England Research Consortium, Muntoni, F., Reilly, M. M., Kurian, M. A., Carr, L., & Munot, P. (2020). KIF1A‐related disorders in children: A wide spectrum of central and peripheral nervous system involvement. Journal of the Peripheral Nervous System, 25, 117–124.
Nicita, F., Ginevrino, M., Travaglini, L., D'Arrigo, S., Zorzi, G., Borgatti, R., Terrone, G., Catteruccia, M., Vasco, G., Brankovic, V., Siliquini, S., Romano, S., Veredice, C., Pedemonte, M., Armando, M., Lettori, D., Stregapede, F., Bosco, L., Sferra, A., … Zanni, G. (2021). Heterozygous KIF1A variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. Journal of Medical Genetics, 58, 475–483.
Ohba, C., Haginoya, K., Osaka, H., Kubota, K., Ishiyama, A., Hiraide, T., Komaki, H., Sasaki, M., Miyatake, S., Nakashima, M., Tsurusaki, Y., Miyake, N., Tanaka, F., Saitsu, H., & Matsumoto, N. (2015). De novo KIF1A mutations cause intellectual deficit, cerebellar atrophy, lower limb spasticity and visual disturbance. Journal of Human Genetics, 60, 739–742.
Okada, Y., Yamazaki, H., Sekine‐Aizawa, Y., & Hirokawa, N. (1995). The neuron‐specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell, 81, 769–780.
Pescosolido, M. F., Schwede, M., Johnson Harrison, A., Schmidt, M., Gamsiz, E. D., Chen, W. S., Donahue, J. P., Shur, N., Jerskey, B. A., Phornphutkul, C., & Morrow, E. M. (2014). Expansion of the clinical phenotype associated with mutations in activity‐dependent neuroprotective protein. Journal of Medical Genetics, 51, 587–589.
Riviere, J. B., Ramalingam, S., Lavastre, V., Shekarabi, M., Holbert, S., Lafontaine, J., Srour, M., Merner, N., Rochefort, D., Hince, P., Gaudet, R., Mes‐Masson, A. M., Baets, J., Houlden, H., Brais, B., Nicholson, G. A., Van Esch, H., Nafissi, S., De Jonghe, P., … Rouleau, G. A. (2011). KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. American Journal of Human Genetics, 89, 219–230.
Saito‐Hakoda, A., Kikuchi, A., Takahashi, T., Yokoyama, Y., Himori, N., Adachi, M., Ikeda, R., Nomura, Y., Takayama, J., Kawashima, J., Katsuoka, F., Fujishima, F., Yamaguchi, T., Ito, A., Hanita, T., Kanno, J., Aizawa, T., Nakazawa, T., Kawase, T., … Kure, S. (2023). Familial Paget's disease of bone with ocular manifestations and a novel TNFRSF11A duplication variant (72dup27). Journal of Bone and Mineral Metabolism, 41, 193–202.
Sakamoto, M., Kouhei, D., Haniffa, M., Silva, S., Troncoso, M., Santander, P., Schonstedt, V., Stecher, X., Okamoto, N., Hamanaka, K., Mizuguchi, T., Mitsuhashi, S., Miyake, N., & Matsumoto, N. (2020). A novel ITPA variant causes epileptic encephalopathy with multiple‐organ dysfunction. Journal of Human Genetics, 65, 751–757.
Takayama, J., Tadaka, S., Yano, K., Katsuoka, F., Gocho, C., Funayama, T., Makino, S., Okamura, Y., Kikuchi, A., Sugimoto, S., Kawashima, J., Otsuki, A., Sakurai‐Yageta, M., Yasuda, J., Kure, S., Kinoshita, K., Yamamoto, M., & Tamiya, G. (2021). Construction and integration of three de novo Japanese human genome assemblies toward a population‐specific reference. Nature Communications, 12, 226.

Auteurs

Aritomo Kawashima (A)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Kaori Kodama (K)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Yukimune Okubo (Y)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Wakaba Endo (W)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Takehiko Inui (T)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Miki Ikeda (M)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Yu Katata (Y)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Noriko Togashi (N)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Chihiro Ohba (C)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Eri Imagawa (E)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kazuhiro Iwama (K)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Takeshi Mizuguchi (T)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Masahiro Kitami (M)

Department of Radiology, Miyagi Children's Hospital, Sendai, Japan.

Yu Aihara (Y)

Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.

Jun Takayama (J)

Department of AI and Innovative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.
Department of Rare Disease Genomics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Gen Tamiya (G)

Department of AI and Innovative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.
Department of Rare Disease Genomics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Atsuo Kikuchi (A)

Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
Department of Rare Disease Genomics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Shigeo Kure (S)

Department of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
Department of Rare Disease Genomics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hirotomo Saitsu (H)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Naomichi Matsumoto (N)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Kazuhiro Haginoya (K)

Department of Pediatric Neurology, Miyagi Children's Hospital, Sendai, Japan.

Classifications MeSH